Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, which is an intravenous injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, an oral injectable small molecule GSI that is in Phase I clinical trial for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.
IPO Year: 2020
Exchange: NASDAQ
Website: ayalapharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/20/2021 | $22.00 | Buy | Maxim Group |
| 12/20/2021 | $18.00 | Buy | HC Wainwright & Co. |
| 11/30/2021 | $12.00 → $17.00 | Hold → Buy | Jefferies |
| 8/17/2021 | $27.00 → $25.00 | Outperform | Oppenheimer |
| 7/13/2021 | $29.00 | Buy | Ladenburg Thalmann |
3 - Old Ayala, Inc (0001797336) (Issuer)
3 - Old Ayala, Inc (0001797336) (Issuer)
3 - Old Ayala, Inc (0001797336) (Issuer)
4 - Old Ayala, Inc (0001797336) (Issuer)
4 - Old Ayala, Inc (0001797336) (Issuer)
4 - Old Ayala, Inc (0001797336) (Issuer)
4 - Old Ayala, Inc (0001797336) (Issuer)
4 - Old Ayala, Inc (0001797336) (Issuer)
4 - Old Ayala, Inc (0001797336) (Issuer)
4 - Old Ayala, Inc (0001797336) (Issuer)
Maxim Group initiated coverage of Ayala Pharmaceuticals with a rating of Buy and set a new price target of $22.00
HC Wainwright & Co. initiated coverage of Ayala Pharmaceuticals with a rating of Buy and set a new price target of $18.00
Jefferies upgraded Ayala Pharmaceuticals from Hold to Buy and set a new price target of $17.00 from $12.00 previously
Oppenheimer reiterated coverage of Ayala Pharmaceuticals with a rating of Outperform and set a new price target of $25.00 from $27.00 previously
Ladenburg Thalmann initiated coverage of Ayala Pharmaceuticals with a rating of Buy and set a new price target of $29.00
Noble Financial resumed coverage of Ayala Pharmaceuticals with a rating of Buy
REHOVOT, Israel and WILMINGTON, Del. and MONMOUTH JUNCTION, N.J., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX:ADXS), a biotechnology company devoted to the discovery, development and commercialization of immunotherapies based on a technology which uses engineered Listeria monocytogenes (Lm), today announced the completion of a previously announced merger with Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers. While the stock will continue to trade on OTC under the symbol ADXS, the merged company will operate under the na
REHOVOT, Israel and WILMINGTON, Del., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers, today is announcing a poster presentation highlighting interim results from the Phase 2 segment / Part A of the RINGSIDE Pivotal Phase 2/3 clinical trial in desmoid tumors at the Connective Tissue Oncology Society (CTOS) 2022 Annual Meeting, taking place in-person November 16-19 in Vancouver, Canada. The ongoing RINGSIDE Pivotal Phase 2/3 clinical trial is evaluating the investigational new drug AL102, a poten
REHOVOT, Israel and WILMINGTON, Del., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers, today announced that the first patient has been dosed in Part B of RINGSIDE, the Phase 3 randomized segment of the trial evaluating AL102 in desmoid tumors. AL102 is a potent, selective, oral gamma-secretase inhibitor (GSI). "We are pleased to begin enrollment in the Phase 3 segment of RINGSIDE, which is a significant milestone in our AL102 development program," said Roni Mamluk, Ph.D., President and Chief Exec
Entered into a definitive merger agreement with Advaxis Inc. – transaction expected to close by end of Q1 2023, subject to approval by Ayala's shareholders and the satisfaction of customary closing conditions Interim positive data from Part A of the RINGSIDE study presented at ESMO demonstrated substantial anti-tumor activity for AL102 as monotherapy and supports continued development AL102 granted Fast Track designation by U.S. FDA for the treatment of progressing desmoid tumors REHOVOT, Israel and WILMINGTON, Del., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule ther
Merger brings U.S. management and presence, cash to develop compelling late-stage asset Lead candidate AL102 being evaluated in ongoing Phase 2/3 RINGSIDE study, a potential registration trial in desmoid tumors Ayala and Advaxis stockholders will respectively own approximately 62.5% and 37.5% Combined Company to Seek Uplisting to Nasdaq Conference Call and Webcast today at 8:00am ET REHOVOT, Israel and WILMINGTON, Del. and MONMOUTH JUNCTION, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA) (Ayala), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressi
Merger brings U.S. management and presence, cash to develop compelling late-stage asset Lead candidate AL102 being evaluated in ongoing Phase 2/3 RINGSIDE study, a potential registration trial in desmoid tumors Ayala and Advaxis stockholders will respectively own approximately 62.5% and 37.5% Combined Company to Seek Uplisting to Nasdaq Conference Call and Webcast today at 8:00am ET REHOVOT, Israel and WILMINGTON, Del. and MONMOUTH JUNCTION, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA) (Ayala), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggress
Event will feature a review of data from part A of the Phase 2/3 RINGSIDE trial of AL102KOLs and management to present on Thursday, October 6th @ 8 AM ET REHOVOT, Israel and WILMINGTON, Del., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers, today announced that it will host a key opinion leader (KOL) webinar on unmet medical needs and evolving treatment landscape of desmoid tumors on Thursday, October 6, 2022, at 8:00 am ET. The webinar will include presentations by Professors Bernd Kasper,
REHOVOT, Israel and WILMINGTON, Del., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for AL102 for the treatment of progressing desmoid tumors. AL102 is a potent, selective, oral gamma-secretase inhibitor. "We are pleased to receive FDA Fast Track designation for AL102 in progressing desmoid tumors, which we believe reinforces the large unmet medical need for patients with this serious disease.
REHOVOT, Israel and WILMINGTON, Del., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced that data on the efficacy and tolerability of investigational new drug AL102 from Part A of the Phase 2/3 RINGSIDE study will be presented in an oral presentation at the European Society for Medical Oncology (ESMO) Congress, to take place September 8-13, 2022 in Paris, France. The presentation details follow: Abstract Title:Initial Results of Phase 2/3 Trial of AL102 for Treatment of Desmoid Tumors
Interim data from Part A of the RINGSIDE study demonstrated substantial initial anti-tumor activity for AL102 as a single agent and supports continued development More advanced and comprehensive data set from RINGSIDE to be presented at ESMO REHOVOT, Israel and WILMINGTON, Del., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, today announced second-quarter 2022 financial results and provided a corporate update. "We continue to make considerable pr
10-K - Old Ayala, Inc (0001797336) (Filer)
15-12G - Old Ayala, Inc (0001797336) (Filer)
8-K - Old Ayala, Inc (0001797336) (Filer)
EFFECT - Old Ayala, Inc (0001797336) (Filer)
EFFECT - Old Ayala, Inc (0001797336) (Filer)
POS AM - Ayala Pharmaceuticals, Inc. (0001797336) (Filer)
S-8 POS - Ayala Pharmaceuticals, Inc. (0001797336) (Filer)
POS AM - Ayala Pharmaceuticals, Inc. (0001797336) (Filer)
25-NSE - Ayala Pharmaceuticals, Inc. (0001797336) (Subject)
8-K - Ayala Pharmaceuticals, Inc. (0001797336) (Filer)
Merger brings U.S. management and presence, cash to develop compelling late-stage asset Lead candidate AL102 being evaluated in ongoing Phase 2/3 RINGSIDE study, a potential registration trial in desmoid tumors Ayala and Advaxis stockholders will respectively own approximately 62.5% and 37.5% Combined Company to Seek Uplisting to Nasdaq Conference Call and Webcast today at 8:00am ET REHOVOT, Israel and WILMINGTON, Del. and MONMOUTH JUNCTION, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA) (Ayala), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressi
Merger brings U.S. management and presence, cash to develop compelling late-stage asset Lead candidate AL102 being evaluated in ongoing Phase 2/3 RINGSIDE study, a potential registration trial in desmoid tumors Ayala and Advaxis stockholders will respectively own approximately 62.5% and 37.5% Combined Company to Seek Uplisting to Nasdaq Conference Call and Webcast today at 8:00am ET REHOVOT, Israel and WILMINGTON, Del. and MONMOUTH JUNCTION, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA) (Ayala), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggress
SC 13G/A - Old Ayala, Inc (0001797336) (Subject)
SC 13G - Old Ayala, Inc (0001797336) (Subject)
SC 13G/A - Old Ayala, Inc (0001797336) (Subject)
SC 13G/A - Old Ayala, Inc (0001797336) (Subject)
SC 13G/A - Ayala Pharmaceuticals, Inc. (0001797336) (Subject)
SC 13G/A - Ayala Pharmaceuticals, Inc. (0001797336) (Subject)
SC 13G/A - Ayala Pharmaceuticals, Inc. (0001797336) (Subject)
SC 13G/A - Ayala Pharmaceuticals, Inc. (0001797336) (Subject)
SC 13G/A - Ayala Pharmaceuticals, Inc. (0001797336) (Subject)
SC 13G/A - Ayala Pharmaceuticals, Inc. (0001797336) (Subject)
Gainers Hepion Pharmaceuticals (NASDAQ:HEPA) stock increased by 72.2% to $0.79 during Tuesday's after-market session. At the close, Hepion Pharmaceuticals's trading volume reached 954.9K shares. This is 348.2% of its average volume over the last 100 days. The market value of their outstanding shares is at $60.3 million. Tivic Health Systems (NASDAQ:TIVC) shares rose 16.89% to $0.64. The company's market cap stands at $6.1 million. Lixte Biotech Hldgs (NASDAQ:LIXT) shares increased by 10.28% to $0.59. The company's market cap stands at $9.8 million. Nutex Health (NASDAQ:NUTX) stock moved upwards by 8.04% to $1.88. The company's market cap stands at $1.2 billion. Alzamend Neuro (NASDAQ:AL
-SEC Filing
On Tuesday, 31 stocks hit new 52-week lows. Things to Consider About Today's 52-Week Lows: The largest company by market cap to hit a new 52-week low was Apple (NASDAQ:AAPL). Tuesday Morning (NASDAQ:TUEM) was the smallest firm by market cap to set a new 52-week low. Biora Therapeutics (NASDAQ:BIOR)'s stock dropped the most, trading down 2329.76% to reach a new 52-week low. Tuesday Morning (NASDAQ:TUEM) shares were the most resilient of the group, as shares actually moved up 0.0% in response to hitting its 52-week low. The following stocks created new 52-week lows on Tuesday: Apple (NASDAQ:AAPL) shares set a new 52-week low of $125.23. The stock traded down 3.12%. Rivian Autom
On Wednesday, 258 companies hit new 52-week lows. Noteworthy Mentions In Today's 52-Week Lows: Amazon.com (NASDAQ:AMZN) was the largest firm on a market cap basis to set a new 52-week low. The smallest company by market cap to set a new 52-week low was Nuwellis (NASDAQ:NUWE). Alset (NASDAQ:AEI) shares traded down 1725.45% to reach its 52-week low, making it the biggest loser. Roku (NASDAQ:ROKU) shares bounced back the most, actually rising 0.0% after hiting a new 52-week low. The following stocks set new 52-week lows on Wednesday: Amazon.com (NASDAQ:AMZN) shares made a new 52-week low of $82.04 on Wednesday. The stock was up 0.13% for the day. Tesla (NASDAQ:TSLA) stock drifte
Gainers 180 Life Sciences (NASDAQ:ATNF) stock rose 75.8% to $2.18 during Tuesday's pre-market session. The company's market cap stands at $4.4 million. HTG Molecular Diagnostics (NASDAQ:HTGM) stock moved upwards by 51.93% to $4.71. The market value of their outstanding shares is at $4.8 million. Invacare (NYSE:IVC) shares rose 42.82% to $0.59. The market value of their outstanding shares is at $22.2 million. Nexalin Technology (NASDAQ:NXL) shares moved upwards by 22.91% to $0.96. The market value of their outstanding shares is at $6.9 million. Innate Pharma (NASDAQ:IPHA) stock rose 14.23% to $3.21. The market value of their outstanding shares is at $257.4 million. KalVista Pharma (NASD
On Thursday, 241 companies hit new 52-week lows. Significant Points From Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was Tesla (NASDAQ:TSLA). Versus Systems (NASDAQ:VS) was the smallest company by market cap to set a new 52-week low. Third Harmonic Bio (NASDAQ:THRD)'s stock traded down the lowest, falling 75.68% to reach a new 52-week low. VirTra (NASDAQ:VTSI) saw the sharpest rebound, as shares ascended 0.0%, reversing after hiting a new 52-week low. On Thursday, the following stocks hit new 52-week lows: Tesla (NASDAQ:TSLA) stock hit a new 52-week low of $153.28. The stock was up 1.08% on the session. M&T Bank (NYSE:MTB) shares moved dow
Gainers Otonomy (NASDAQ:OTIC) shares increased by 114.7% to $0.23 during Tuesday's regular session. The current volume of 184.8 million shares is 6152.7% of Otonomy's average full-day volume over the last 100 days (last updated at 12:30 EST). The market value of their outstanding shares is at $13.1 million. Apollo Endosurgery (NASDAQ:APEN) shares increased by 65.41% to $9.93. As of 12:30 EST, Apollo Endosurgery's stock is trading at a volume of 22.6 million, which is 21929.3% of its average full-day volume over the last 100 days. The company's market cap stands at $413.2 million. OncoSec Medical (NASDAQ:ONCS) stock increased by 23.13% to $3.14. The current volume of 13.2 million shares is
On Friday, 63 stocks hit new 52-week lows. Interesting Points From Today's 52-Week Lows: Algonquin Power (NYSE:AQN) was the biggest company in terms of market cap to set a new 52-week low. The smallest company on a market cap basis to set a new 52-week low was First Wave BioPharma (NASDAQ:FWBI). Blue Apron Hldgs (NYSE:APRN)'s stock came under the most pressure, trading down 29.9% to reach a new 52-week low. Cardio Diagnostics Hldgs (NASDAQ:CDIO) shares were the most resilient, as shares rose 0.0%, rebounding from its new 52-week low. The stocks that set new 52-week lows on Friday: Algonquin Power (NYSE:AQN) shares hit a yearly low of $9.28. The stock was down 14.9% on the sess
Ayala Pharmaceuticals (NASDAQ:AYLA) reported its Q3 earnings results on Friday, November 4, 2022 at 08:00 AM. Here's what investors need to know about the announcement. Earnings Ayala Pharmaceuticals missed estimated earnings by 34.69%, reporting an EPS of $-0.66 versus an estimate of $-0.49. Revenue was down $534 thousand from the same period last year. Past Earnings Performance Last quarter the company beat on EPS by $0.07 which was followed by a 8.0% increase in the share price the next day. Listen to the earnings announcement yourself by clicking here. To track all earnings releases for Ayala Pharmaceuticals visit their earnings calendar here. This article was generated by B